基于单束优化的自适应计划在胰腺癌被动散射碳离子放疗中的应用
本研究纳入8例胰腺癌患者和95套每日CT,评估基于新距离补偿器(AP-1)和初始距离补偿器(AP-2)的自适应计划在被动散射碳离子放疗中的剂量学表现。结果显示AP-1和AP-2均能维持满意的累积剂量,但AP-2导致十二指肠剂量增加,尤其左右束方向。
要点
- 骨匹配和肿瘤匹配均可能出现剂量覆盖下降,需考虑自适应再计划。
- 基于单束优化的自适应计划可维持胰腺癌被动散射碳离子放疗的剂量稳健性。
- AP-2可能增加十二指肠剂量,需进一步研究正常组织保护。
核心结论
- 基于单束优化的被动散射碳离子放疗再计划是确保胰腺癌治疗稳健性的有效且安全的方法。
研究设计与样本
- 研究纳入8例胰腺癌患者和95套每日CT,生成基于新距离补偿器的AP-1和基于初始距离补偿器的AP-2两种自适应计划,并与骨匹配和肿瘤匹配的原始计划剂量比较,使用基于轮廓和强度的可变形图像配准算法计算累积剂量。
主要发现
- 肿瘤匹配和骨匹配的每日CTV V95(%)相对原始计划的差值分别为-5.1±6.2和-8.8±8.8,而AP-1为1.2±3.4、AP-2为-0.5±2.1(P<0.001)。
- AP-1和AP-2在所有患者中均维持满意的累积剂量。
- AP-1、AP-2、肿瘤匹配和骨匹配的剂量差值分别为1.2±2.8、-2.1±1.7、-7.1±5.2和-16.5±15.0。
- AP-2导致十二指肠剂量增加,尤其在左右束方向。
临床怎么用
- 行骨匹配甚至肿瘤匹配时需考虑可能的剂量劣化,必要时采用基于单束优化的自适应再计划。
- 使用AP-2时需关注十二指肠剂量增加,尤其左右束方向。
局限性
- 需进一步研究以保护健康组织,尤其是十二指肠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Daily anatomical deviations may distort the dose distribution in carbon ion radiotherapy (CIRT), which may cause treatment failure. Therefore, this study aimed to perform re-planning to maintain the dose coverage in patients with pancreatic cancer with passive scattering CIRT. METHODS: Eight patients with pancreatic cancer and 95 daily computed tomography (CT) sets were examined. Two types of adaptive plans based on new range compensators (RCs) (AP-1) and initial RCs (AP-2) were generated. In AP-2, each beam was optimized by manually adjusting the range shifter thickness and spread-out Bragg peak size to make dose reduction by < 3% of the original plan. Doses of the original plan with bone matching (BM) and tumor matching (TM) were examined for comparison. We calculated the accumulated dose using the contour and intensity-based deformable image registration algorithm. The dosimetric differences in respect to the original plan were compared between methods. RESULTS: Using TM and BM, mean ± standard deviations of daily CTV V95 (%) difference from the original plan was - 5.1 ± 6.2 and - 8.8 ± 8.8, respectively, but 1.2 ± 3.4 in AP-1 and - 0.5 ± 2.1 in AP-2 (P < 0.001). AP-1 and AP-2 enabled to maintain a satisfactory accumulated dose in all patients. The dose difference was 1.2 ± 2.8, - 2,1 ± 1.7, - 7.1 ± 5.2, and - 16.5 ± 15.0 for AP-1, AP-2, TM, and BM, respectively. However, AP-2 caused a dose increase in the duodenum, especially in the left-right beam. CONCLUSIONS: The possible dose deterioration should be considered when performing the BM, even TM. Re-planning based on single beam optimization in passive scattering CIRT seems an effective and safe method of ensuring the treatment robustness in pancreatic cancer. Further study is necessary to spare healthy tissues, especially the duodenum.
引用
- Li Y, Kubota Y, Okamoto M, et al. Adaptive planning based on single beam optimization in passive scattering carbon ion radiotherapy for patients with pancreatic cancer. Radiat Oncol. 2021. PMID: 34147099. doi:10.1186/s13014-021-01841-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。